Method for the treatment of lipid and glucose metabolism disorders
US6855707B2 · kind B2 · utility
56Cited by
11References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 10, 2001 |
| Grant date | Feb 15, 2005 |
| Priority date | — |
| Expiry date | Sep 10, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/58
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate subject a D1 dopamine agonist in conjunction with a dopamine D2 agonist where the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein. In preferred embodiments, the administration of the D1 dopamine agonist and the D2 dopamine agonist is conducted at a predetermined time.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.